Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has submitted to BSE a routine compliance certificate from its Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., for the quarter ended June 30, 2025. The certificate confirms that share certificates received for dematerialization during the quarter were processed, verified, and the names of depositories substituted as registered owners within SEBI-prescribed timelines. The attached details show 1,800 shares (across 18 certificates of 100 shares each) were dematerialized by two shareholders — Sushilkumar Santoshkumar Khandelwal (800 shares on April 26, 2025) and Geeta Rana (1,000 shares on May 27, 2025). The company has an ISIN of INE194R01017 and BSE scrip code 539730. The filing was signed by Managing Director Fredun Nariman Medhora on July 9, 2025.
This is a standard regulatory compliance filing with no material impact on the company's operations, financials, or share price. It simply confirms routine processing of shareholder dematerialization requests for Q1 FY26.